Archive for the ‘Health & Obesity’ Category

Moving from Hype to Realities in the Obesity Market

February 7, 2025 — Novo Nordisk and Lilly reported on their business results this week for the final quarter of 2024. These reports brought clarity on a number of points, but to us, one thing stands out. We are moving from euphoria and hype about limitless possibilities in obesity to the realities of market competition and incremental progress. Sales […]

A Spoonful of Microplastics in Our Brain Can’t Be Good

February 6, 2025 — From the category of stuff that can’t be good. a study in Nature Medicine this week documents a spoonful of microplastics accumulating in an typical human brain. Alexander Nihart and colleagues used diverse methods to detect microplastics in various tissues (kidney, liver, and brain) of deceased individuals from 2016 and 2024. They found these particles […]

Have Overweight and Obesity Peaked at 75% of the Population?

February 5, 2025 — Yesterday, another report came out to suggest that the prevalence of obesity and overweight may have peaked in the American population – at a combined prevalence of 75%. This particular report comes from Epic Research, based on electronic health records for more than 100 million patients. Every time one of these reports emerges, headlines are […]

Growing Calls for Drug Labels to Include People with Obesity

February 4, 2025 — Chasing the possibility of multi-billion dollar obesity medicines, pharmaceutical companies are jumping at the chance to spend billions in clinical research. But patient advocates find a reluctance from some of those same companies to take people with obesity into account in the drug labels for their products already on the market. Writing for In Vivo, […]

Disparities in GLP-1 Medicines for Obesity Are Growing Obvious

February 3, 2025 — A new study in JAMA Network Open makes one thing very clear. Most people who take GLP-1 medicines for obesity quit within a year. Most who take them for diabetes are less likely to quit. Why are the disparities in GLP-1 medicines for obesity so great in comparison to their use for diabetes? It’s all […]

The Radical Reversal in Attitudes About Obesity Medicines

February 2, 2025 — On Friday, the AP-NORC Center for Public Affairs Research documented a remarkable reversal in attitudes about obesity medicines. Roughly half of the public believes “it’s a good idea” to use obesity medicines for obesity or weight-related health conditions. Likewise, most Americans believe Medicare and Medicaid should cover the use of these drugs. Only about 20% […]

Forget Cake – Let Them Eat Whole Foods

February 1, 2025 — The sincerity and passion of Dariush Mozaffarian is easy to recognize and admire. His deep belief in the opportunity for good food to make us healthier is familiar. It echoes the impassioned pitch of a politician before Senate hearings this week. Too many Americans have too many “diet-related” diseases. Time’s a wastin’! Let them all […]

Obesity, Diabetes Prevention, and Angels Dancing on a Pinhead

January 31, 2025 — For persons with obesity and prediabetes, one of the best ways to prevent diabetes onset is quite clear. Treat the obesity to reduce the excess adiposity. The Diabetes Prevention Program established this with a study in the NEJM way back in 2002. A prescription of diet and exercise could cut the risk of diabetes in […]

The Dizzy Pace of Change in Prescribing for Obesity Care

January 30, 2025 — A new paper in JAMA Network Open documents just how dizzy the pace of change in prescribing for obesity care has been in the last seven years. Prescriptions for obesity medicines have doubled. Phentermine prescribing has grown – it’s generic, cheap, and effective. Even now, it accounts for almost half of obesity medicine prescriptions. But […]

FDA Approves Ozempic to Prevent Kidney Failure and Death

January 29, 2025 — FDA yesterday approved Ozempic (semaglutide) to prevent kidney failure and death in persons with type 2 diabetes and chronic kidney disease. This fits with one of the five trends for this year: the steady expansion of health benefits for advanced medicines used in obesity and diabetes. But note that this approval covers the use of […]